Zinc for Carcinoma

Phase-Based Estimates
1
Effectiveness
1
Safety
Emory University Hospital/Winship Cancer Institute, Atlanta, GA
Carcinoma+7 More
Zinc - DietarySupplement
Eligibility
Any Age
All Sexes
Eligible conditions
Carcinoma

Study Summary

This study is evaluating whether zinc may help to improve quality of life in patients with gastrointestinal cancer.

See full description

Eligible Conditions

  • Carcinoma
  • Cancer of Pancreas
  • Cancer of Esophagus
  • Cancer of Stomach
  • Gastric Carcinoma
  • Liver and Intrahepatic Bile Duct Carcinoma
  • Unresectable Esophageal Carcinoma
  • Unresectable Pancreatic Carcinoma
  • Pancreatic Neoplasms
  • Esophageal Neoplasms
  • Stomach Neoplasms

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether Zinc will improve 1 primary outcome and 2 secondary outcomes in patients with Carcinoma. Measurement will happen over the course of Up to 4 months after study start.

Month 4
Quality of life scores
Serum albumin level
Serum zinc level

Trial Safety

Safety Estimate

1 of 3

Side Effects for

Separate Iron and Zinc
infectious hospitalizations
4%
noninfectious hospitalizations
1%
This histogram enumerates side effects from a completed 2008 Phase 4 trial (NCT00470158) in the Separate Iron and Zinc ARM group. Side effects include: infectious hospitalizations with 4%, noninfectious hospitalizations with 1%.

Trial Design

2 Treatment Groups

No Control Group
Group I (zinc months 1 and 2)

This trial requires 17 total participants across 2 different treatment groups

This trial involves 2 different treatments. Zinc is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Group I (zinc months 1 and 2)
DietarySupplement
Patients receive zinc PO TID for months 1 and 2 only of the first 4 months on therapy.
Group II (zinc months 3 and 4)
DietarySupplement
Patients receive zinc PO TID for months 3 and 4 only of the first 4 months on therapy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Zinc
2005
Completed Phase 4
~17050

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 4 months after study start
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly up to 4 months after study start for reporting.

Who is running the study

Principal Investigator
A. T. J.
Aaron T. Jones, Principal Investigator
Emory University

Closest Location

Emory University Hospital/Winship Cancer Institute - Atlanta, GA

Eligibility Criteria

This trial is for patients born any sex of any age. You must have received newly diagnosed for Carcinoma or one of the other 7 conditions listed above. There are 4 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
satellite location Patients plan to receive chemotherapy at an off-campus location affiliated with the Emory Cancer Center. show original
A study found that patients with newly diagnosed gastric, gastro-esophageal, pancreas or biliary cancer who did not receive prior chemotherapy or radiation therapy had a significantly improved overall survival rate. show original
, or those with a known diagnosis of Stage IV cancer, will be offered enrollment in a multicenter clinical trial show original
form to receive treatment In order to receive treatment, patients must sign an informed consent form show original

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are common treatments for carcinoma?

Add answer

Carcinomas may present with a variety of symptoms. Common treatments include surgery (or surgery with radiation or chemotherapy), chemotherapy, immunotherapy (e.g., rituximab, trastuzumab), and radiotherapy. Most carcinomas have no cure, but some do have a cure (eg, melanoma and renal cell carcinoma). The 5-year survival rate may be around 30% for surgically resected renal cell carcinoma and 15% for lung cancer.

Unverified Answer

How many people get carcinoma a year in the United States?

Add answer

The number of cases of carcinoma diagnosed in the US in any given year is dependent on the prevalence of the disease. Recent findings underscore the need for careful and comprehensive epidemiologic studies in populations that will aid in planning and programmatic planning for cancers in high-prevalence or high-risk populations.

Unverified Answer

What is carcinoma?

Add answer

Carcinoma is the most common type of malignancy present in the brain. Treatment is largely palliative in the majority of cases, and the 5-year survival rate is only 20%. A multidisciplinary management plan is the most important variable in determining survival. Brain tumour is a separate entity from brain metastatic carcinomas. Carcinomas of the brain are classified based on their location and in order to provide patients with a reasonable outcome.

Unverified Answer

What causes carcinoma?

Add answer

Chronic inflammation, such as that caused by smoking, is a plausible mechanism for carcinogenesis. The role of infection with human papillomavirus is suggested by its increasing frequency in epithelial carcinomas, but its role is yet to be determined.

Unverified Answer

Can carcinoma be cured?

Add answer

Carcinoma of the cervix is strongly associated with poor survival rate in early stage because of the failure of adequate treatment. There are various ways to decrease the local and distant disease recurrence, such as radiotherapy, chemotherapy or the use of hormonotherapy. The cure rate of carcinoma varies with the cancer-type. However, it is still a very serious task to cure the carcinoma.

Unverified Answer

What are the signs of carcinoma?

Add answer

The signs of carcinoma could be distinguished based on their clinical presentation, and the diagnosis could be easily missed. The development of consensus guidelines would be useful in the future.

Unverified Answer

How serious can carcinoma be?

Add answer

The prevalence of carcinoma of colon is 1.5 million cases per year in the U.S.; in Finland a 5-year incidence of colorectal carcinoma in whites has been estimated to be around 20/10 000, whereas in blacks this number is around 50/10 000. Thus, in Finland carcinoma of colon is roughly as common for whites as it is in blacks in the United States. Carcinoma of the colon causes approximately 20% of death, and 15% of death due to cancer in the U.S.

Unverified Answer

What is the average age someone gets carcinoma?

Add answer

Approximately 1 in 3 people had carcinoma at the age of 40, and there is evidence that the proportion will continue to increase. Cancers of the head and neck will present earlier to the patient, but this will be offset by a higher proportion of cancers presenting at a later age. Further work must determine whether these factors will be important in the planning of cancer services.

Unverified Answer

Have there been any new discoveries for treating carcinoma?

Add answer

There are a number of new findings that are being tested in order to treat carcinoma. By searching the National Cancer Institute's website, you will be able to view the list of cancer treatments in the future. Because the treatments for cancer continue to change, your doctor will be able to recommend the best course of action for you.\n

Unverified Answer

What is the latest research for carcinoma?

Add answer

The studies on carcinoma are evolving rapidly as the cancer research progresses. The following are some of the interesting recent developments in carcinoma research. (1) The number of new molecular subtype studies in carcinoma has risen considerably. (2) Cancer stem cell research has become increasingly important as the target of anticancer. (3) Novel biologic therapies have been developed for some carcinoma. (4) There has been development of tumor biomarkers for early detection of carcinoma at its early stage. (5) Cancer immunotherapy has shown much promise in developing an effective response in patients with carcinoma. (6) Cancer vaccine is a promising approach to overcome some of the limitations of cancer.

Unverified Answer

How quickly does carcinoma spread?

Add answer

A recent case-control study identified two patients having a high risk of disseminated disease who did not obtain clinical clearance, despite the development of a clinical suspicion of carcinoma. In these two patients the clinical course was not favorable: they were still alive, but died of other causes, in 4 and 8.5 months, respectively. There is no precise timing parameter in this form of carcinoma dissemination and there is no agreement about the necessity, or even the possibility, of applying specific treatment to high risk patients.

Unverified Answer

What is the primary cause of carcinoma?

Add answer

Although there are many factors that contribute to the development of carcinoma, primary malignancy remains the most significant component of carcinoma and, by extension, the primary treatment of carcinoma. In particular, primary carcinoma contributes over 10% to the overall mortality rate in patients with carcinoma, making it the most common cause of mortality. To help physicians in their treatment of patients with carcinoma, we provide a list of the leading causes of primary carcinoma and propose possible treatment strategies for each primary carcinoma based on the mechanism by which it develops.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Carcinoma by sharing your contact details with the study coordinator.